Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a robust pipeline of drugs for multiple medical and defense applications.
The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. CBLI’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.
Contact Details
Executives
Co-founder, Chief Exec. Officer, Pres, Member of Management Board
Dr. Michael Fonstein Ph.D.
Co-Founder, Chief Operating Officer, Sec.
Dr. Yakov N. Kogan Ph.D., M.B.A.